Source and scope
This summary is bounded to the recommendations, population and decisions covered by Guideline on male lower urinary tract symptoms and benign prostatic hyperplasia. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CUA LUTS/BPH
Source-attributed clinical priorities
- Measure symptom burden and bother and assess urinalysis, retention, medicines, neurologic disease and prostate-cancer concerns.
- Use lifestyle, medication and procedural options according to phenotype, prostate features, adverse effects and goals.
- Refer retention, recurrent infection, stones, renal impairment, hematuria or failed initial management.
- Use a bladder diary and symptom score to distinguish storage, voiding and nocturnal-polyuria patterns.
sources for this section:CUA LUTS/BPH
Practical assessment and management workflow
1
Assess bother, onset, fluids, medicines, diabetes, sleep apnea, neurologic symptoms, hematuria and infection.
2
Examine abdomen and prostate when indicated and obtain urinalysis and selective residual urine or flow testing.
3
Choose behavioural, alpha-blocker, 5-alpha-reductase or bladder-directed treatment by phenotype.
4
Review symptoms, blood pressure, sexual effects and residual urine and refer complications or nonresponse.
sources for this section:CUA LUTS/BPH
Safety, red flags and urgent escalation
- Retention, urosepsis, renal impairment or clot obstruction requires urgent urologic care.
- Hematuria or suspected cancer needs a separate diagnostic pathway.
- Avoid anticholinergic treatment when significant retention risk has not been assessed.
sources for this section:CUA LUTS/BPH
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CUA LUTS/BPH
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CUA LUTS/BPH
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Urological AssociationGuideline on male lower urinary tract symptoms and benign prostatic hyperplasiaaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.